Bruno C. Huber

Dr. Bruno C. Huber


Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 June 2014 in Nature Methods
Verified
Journal Article
Open access
PDF file
PBPaul W Burridge
Paul W Burridge
EMElena Matsa
Elena Matsa
PSPraveen Shukla
Praveen Shukla
ZLZiliang C Lin
Ziliang C Lin
JCJared M Churko
Jared M Churko
JWJoseph C Wu
Joseph C Wu
A simple, robust, chemically defined method for generating cardiomyocytes from human pluripotent stem cells is described. It should enable the identification of conditions for maturation of these cells. Existing methods for human induced pluripotent stem cell (hiPSC) cardiac differentiation are efficient but require complex, undefined medium constituents that hinder further elucidation of the molecular mechanisms of cardiomyogenesis. Using hiPSCs derived under chemically defined conditions on synthetic matrices, we systematically developed an optimized cardiac differentiation strategy, using a chemically defined medium consisting of just three components: the basal medium RPMI 1640, L-ascorbic acid 2-phosphate and rice-derived recombinant human albumin. Along with small molecule–based induction of differentiation, this protocol produced contractile sheets of up to 95% TNNT2+ cardiomyocytes at a yield of up to 100 cardiomyocytes for every input pluripotent cell and was effective in 11 hiPSC lines tested. This chemically defined platform for cardiac specification of hiPSCs will allow the elucidation of cardiomyocyte macromolecular and metabolic requirements and will provide a minimal system for the study of maturation and subtype specification.

1 April 2009 in Cell Stem Cell
Verified
Journal Article
Closed access
MZMarc-Michael Zaruba
Marc-Michael Zaruba
HTHans Diogenes Theiss
Hans Diogenes Theiss
MVMarkus Vallaster
Markus Vallaster
UMUrsula Mehl
Ursula Mehl
SBStefan Brunner
Stefan Brunner
WFWolfgang-Michael Franz
Wolfgang-Michael Franz

24 September 2014 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
AEAntje D. Ebert
Antje D. Ebert
KKKazuki Kodo
Kazuki Kodo
PLPing Liang
Ping Liang
HWHaodi Wu
Haodi Wu
BHBruno C. Huber
Bruno C. Huber
JWJoseph C. Wu
Joseph C. Wu
The decrease of function in the ALDH2*2 genotype disrupts an important cardioprotective oxidative stress regulatory circuit, thus increasing cardiac cell death after ischemic insult.

1 August 2014 in JACC
Verified
Journal Article
Closed access
VSVeronica Sanchez-Freire
Veronica Sanchez-Freire
ALAndrew S. Lee
Andrew S. Lee
SHShijun Hu
Shijun Hu
OAOscar J. Abilez
Oscar J. Abilez
PLPing Liang
Ping Liang
JWJoseph C. Wu
Joseph C. Wu

14 September 2012 in Circulation Research
Verified
Journal Article
Closed access
MGMingxia Gu
Mingxia Gu
PNPatricia K. Nguyen
Patricia K. Nguyen
ALAndrew S. Lee
Andrew S. Lee
DXDan Xu
Dan Xu
SHShijun Hu
Shijun Hu
JWJoseph C. Wu
Joseph C. Wu
Rationale:: Induced pluripotent stem cells (iPSCs) hold great promise for the development of patient-specific therapies for cardiovascular disease. However, clinical translation will require preclinical optimization and validation of large-animal iPSC models. Objective:: To successfully derive endothelial cells from porcine iPSCs and demonstrate their potential utility for the treatment of myocardial ischemia. Methods and Results:: Porcine adipose stromal cells were reprogrammed to generate porcine iPSCs (piPSCs). Immunohistochemistry, quantitative PCR, microarray hybridization, and angiogenic assays confirmed that piPSC-derived endothelial cells (piPSC-ECs) shared similar morphological and functional properties as endothelial cells isolated from the autologous pig aorta. To demonstrate their therapeutic potential, piPSC-ECs were transplanted into mice with myocardial infarction. Compared with control, animals transplanted with piPSC-ECs showed significant functional improvement measured by echocardiography (fractional shortening at week 4: 27.2±1.3% versus 22.3±1.1%; P <0.001) and MRI (ejection fraction at week 4: 45.8±1.3% versus 42.3±0.9%; P <0.05). Quantitative protein assays and microfluidic single-cell PCR profiling showed that piPSC-ECs released proangiogenic and antiapoptotic factors in the ischemic microenvironment, which promoted neovascularization and cardiomyocyte survival, respectively. Release of paracrine factors varied significantly among subpopulations of transplanted cells, suggesting that transplantation of specific cell populations may result in greater functional recovery. Conclusions:: In summary, this is the first study to successfully differentiate piPSCs-ECs from piPSCs and demonstrate that transplantation of piPSC-ECs improved cardiac function after myocardial infarction via paracrine activation. Further development of these large animal iPSC models will yield significant insights into their therapeutic potential and accelerate the clinical translation of autologous iPSC-based therapy.

1 November 2011 in Stem Cell Research
Verified
Journal Article
Open access
HTHans D. Theiss
Hans D. Theiss
MVMarkus Vallaster
Markus Vallaster
CRChristoph Rischpler
Christoph Rischpler
LKLisa Krieg
Lisa Krieg
MZMarc-Michael Zaruba
Marc-Michael Zaruba
WFWolfgang-M. Franz
Wolfgang-M. Franz
G-CSF based stem cell mobilization and stabilization of cardiac SDF-1 by DPP-IV-inhibition (dual stem cell therapy) improve heart function and survival after myocardial infarction. However, it is barely understood whether this new approach acts specifically through the SDF-1/CXCR4 axis, stimulation of resident cardiac stem cells and improved myocardial perfusion. Therefore, we aimed to clarify the role of the SDF1/CXCR4 axis with respect to the benefits of a dual stem cell based therapy. After surgically induced ligation of the LAD, SDF-1/CXCR4 interactions were specifically blocked by the CXCR4 receptor antagonist AMD3100 in G-CSF and Diprotin A treated C57BL/6 mice. G-CSF+DipA treated and non-treated animals served as controls. Because AMD3100 is known to mobilize bone marrow derived stem cells (BMCs) in high concentrations, the optimal dosage (1.25mg per kg body weight) sufficient to block CXCR4 without stimulating mobilization was established. AMD3100 treatment of G-CSF and Diprotin A stimulated mice significantly decreased myocardial homing of circulating stem cells (FACS analysis) and inverted the beneficial effects of (i) cardiac remodeling (histological analyses), (ii) heart function (Millar tip catheterization) and (iii) survival (Kaplan-Meier curves). G-CSF treatment in combination with DPP-IV inhibition enhanced neovascularization at the infarct border zone which was related to an improved myocardial blood flow as measured by SPECT. Moreover, dual stem cell treatment effectively stimulated the pool of resident cardiac stem cells (FACS) which was reversed by AMD3100 treatment. Our data give final proof that homing through the SDF-1/CXCR-4 axis is essential for the success of dual stem cell therapy.